Log in
Enquire now
‌

US Patent 10973825 Thienopyrimidinone NMDA receptor modulators and uses thereof

Patent 10973825 was granted and assigned to Cadent Therapeutics on April, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Cadent Therapeutics
Cadent Therapeutics
0
Current Assignee
Cadent Therapeutics
Cadent Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
109738250
Patent Inventor Names
Christopher Fanger0
Robert A. Volkmann0
David R. Anderson0
Frank S. Menniti0
Date of Patent
April 13, 2021
0
Patent Application Number
160602670
Date Filed
December 9, 2016
0
Patent Citations Received
‌
US Patent 11541057 Thienopyrimidinone NMDA receptor modulators and uses thereof
‌
US Patent 11542264 Heteroaromatic NMDA receptor modulators and uses thereof
0
‌
US Patent 11648253 Thienopyrimidinone NMDA receptor modulators and uses thereof
0
Patent Primary Examiner
‌
Sahar Javanmard
0
Patent abstract

Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10973825 Thienopyrimidinone NMDA receptor modulators and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.